OTC · HSTC
HST Global, Inc.
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
OTC · STAB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Statera Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Statera Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting antigen-specific killer T-cells and antibodies to activate crucial defenses against inflammatory, infectious, and cancerous diseases. Statera BioPharma's clinical pipeline features programs such as STAT-201 for Crohn's disease, Entolimod for hematological conditions, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company is also actively exploring therapeutic applications for fibromyalgia and multiple sclerosis. Formerly known as Cytocom, Inc., the company officially adopted the name Statera BioPharma, Inc. in September 2021. Its operations are headquartered in Fort Collins, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.04+$0.01 (+19.6%)
Oncology Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.11% below the high.
$0.00$0.00 (0.0%)
Entia Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.52% below the high.
$0.00$0.00 (0.0%)
Bloomios, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Biostax Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
$0.00$0.00 (0.0%)
SES Solar Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Better Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
